<DOC>
	<DOCNO>NCT02788708</DOCNO>
	<brief_summary>This phase I trial study side effect best dose lenvatinib mesylate give together paclitaxel treat patient endometrial , ovarian , fallopian tube , primary peritoneal cancer come back grow . Lenvatinib mesylate may stop growth tumor cell block protein need cell growth may block growth new blood vessel necessary tumor growth . Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell , stop dividing , stop spread . Giving lenvatinib mesylate paclitaxel together may work well treat patient endometrial , ovarian , fallopian tube , primary peritoneal cancer .</brief_summary>
	<brief_title>Lenvatinib Weekly Paclitaxel Patients With Recurrent Endometrial Ovarian Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine recommended phase II dose ( RPTD ) combination lenvatinib mesylate ( lenvatinib ) weekly paclitaxel patient recurrent endometrial , epithelial ovarian , primary peritoneal , fallopian tube carcinoma . SECONDARY OBJECTIVES : I . To determine safety tolerability combination lenvatinib weekly paclitaxel patient recurrent endometrial , epithelial ovarian , primary peritoneal , fallopian tube carcinoma . II . To explore objective antitumor activity ( complete partial response ) combination lenvatinib weekly paclitaxel measure Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . III . To measure progression free survival . IV . To evaluate pharmacokinetics combination paclitaxel lenvatinib . OUTLINE : This dose -escalation study lenvatinib mesylate . Patients receive paclitaxel intravenously ( IV ) 1 hour day 1 , 8 , 15 lenvatinib mesylate orally ( PO ) daily ( QD ) day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 3 month 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Women histologically confirm endometrial cancer , epithelial ovarian cancer , fallopian tube cancer , primary peritoneal cancer ( histological subtypes ) disease progression treatment available therapy know confer clinical benefit intolerant prior treatment Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record nonnodal lesion short axis nodal lesion ) ≥ 20 mm conventional technique ≥10 mm spiral computerize tomography ( CT ) scan , magnetic resonance imaging ( MRI ) , caliper clinical exam Patients must receive prior treatment platinum contain regimen may receive unlimited number prior regimen ( include prior taxanes ) Patients ovarian , Fallopian tube primary peritoneal cancer must platinum resistant ( progression &lt; 6 month completion platinum contain regimen ) Patients may receive prior target therapy bevacizumab Eastern Cooperative Oncology Group performance status = &lt; 1 Leukocytes &gt; = 3,000/mcL ( microliter ) Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Hemoglobin &gt; =8.0 g/dL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamic pyruvic transaminase [ SGPT ] ) = &lt; 2.5 × institutional upper limit normal Creatinine &lt; 1.5 mg/dL X ULN OR creatinine clearance &gt; = 30 mL/min patient creatinine level institutional normal Urine protein dipstick &lt; 1+ UPC = &lt; 1.0 urinalysis Patients chronic hypertension well control systolic blood pressure &lt; 140 mmHg diastolic blood pressure &lt; 90 mmHg , change blood pressure medication last two week , eligible Patients history deep vein thrombosis ( DVT ) pulmonary embolus stable anticoagulation &gt; 1 month eligible</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>paclitaxel</keyword>
	<keyword>lenvatinib</keyword>
</DOC>